Current Hematologic Malignancy Reports 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions
AbstractPurpose of ReviewThe clinical scenario for chronic myeloid leukemia patients rapidly changed after the introduction of tyrosine kinase inhibitors (TKIs). Second-generation TKIs as frontline treatment increased the rate of deep molecular responses without increasing the rate of overall survival. About 20% of patients experience resistance to these agents, needing alternative treatments. Here, we reviewed the possible mechanisms of resistance, available treatment, and new drugs developed to counteract and overcome resistance.Recent FindingsResults of novel TKIs have been recently reported, especially for the setting ...
Source: Current Hematologic Malignancy Reports - December 1, 2022 Category: Hematology Source Type: research
Molecular Pathogenesis of Myeloproliferative Neoplasms
AbstractPurpose of ReviewMyeloproliferative neoplasms (MPNs) are chronic hematological malignancies characterized by increased proliferation of MPN stem and myeloid progenitor cells with or without bone marrow fibrosis that typically lead to increased peripheral blood cell counts. The genetic and cytogenetic alterations that initiate and drive the development of MPNs have largely been defined, and we summarize these here.Recent FindingsIn recent years, advances in understanding the pathogenesis of MPNs have defined a long-preclinical phase inJAK2-mutant MPN, identified genetic loci associated with MPN predisposition and un...
Source: Current Hematologic Malignancy Reports - December 1, 2022 Category: Hematology Source Type: research
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
AbstractPurpose of ReviewMultiple myeloma (MM) is a hematologic malignancy of plasma cells that remains incurable with currently available therapies including proteosome inhibitors, immunomodulators, monoclonal antibodies, corticosteroids, and alkylators, in addition to autologous stem cell transplantation in patients who are eligible. Novel therapeutics are therefore required to improve patient outcomes. The goal of this paper is to review the role of three new agents in the MM treatment landscape: belantamab mafodotin, selinexor, and melflufen.Recent FindingsAll three agents have demonstrated clinical activity in patient...
Source: Current Hematologic Malignancy Reports - December 1, 2022 Category: Hematology Source Type: research
Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies
AbstractPurpose of ReviewHematologic malignancies were previously thought to be primarily sporadic cancers without germline predispositions. However, over the last two decades, with the widespread use of next generation sequencing (NGS), there have been several genes have been identified that carry a risk of inheriting hematologic malignancies. Identification of individuals with hereditary hematologic malignancies (HHM) involves a high index of suspicion and careful attention to family history, clinical features, and variant allele frequency on somatic NGS pan els.Recent FindingsOver the last several years, many genetic ...
Source: Current Hematologic Malignancy Reports - December 1, 2022 Category: Hematology Source Type: research
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies
AbstractPurpose of ReviewDespite the adoption of tyrosine kinases inhibitors (TKIs) as molecular targeted therapy in chronic myeloid leukemia, some patients do not respond to treatment and even experience disease progression. This review aims to give a broad summary of advances in understanding of the mechanisms of therapy resistance, as well as management strat egies that may overcome or prevent the emergence of drug resistance. Ultimately, the goal of therapy is the cure of CML, which will also require an increased understanding of the leukemia stem cell (LSC).Recent FindingsResistance to tyrosine kinase inhibitors ste...
Source: Current Hematologic Malignancy Reports - December 1, 2022 Category: Hematology Source Type: research
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
AbstractPurpose of ReviewMultiple myeloma (MM) is a hematologic malignancy of plasma cells that remains incurable with currently available therapies including proteosome inhibitors, immunomodulators, monoclonal antibodies, corticosteroids, and alkylators, in addition to autologous stem cell transplantation in patients who are eligible. Novel therapeutics are therefore required to improve patient outcomes. The goal of this paper is to review the role of three new agents in the MM treatment landscape: belantamab mafodotin, selinexor, and melflufen.Recent FindingsAll three agents have demonstrated clinical activity in patient...
Source: Current Hematologic Malignancy Reports - November 22, 2022 Category: Hematology Source Type: research
Molecular Pathogenesis of Myeloproliferative Neoplasms
AbstractPurpose of ReviewMyeloproliferative neoplasms (MPNs) are chronic hematological malignancies characterized by increased proliferation of MPN stem and myeloid progenitor cells with or without bone marrow fibrosis that typically lead to increased peripheral blood cell counts. The genetic and cytogenetic alterations that initiate and drive the development of MPNs have largely been defined, and we summarize these here.Recent FindingsIn recent years, advances in understanding the pathogenesis of MPNs have defined a long-preclinical phase inJAK2-mutant MPN, identified genetic loci associated with MPN predisposition and un...
Source: Current Hematologic Malignancy Reports - November 7, 2022 Category: Hematology Source Type: research
Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies
AbstractPurpose of ReviewHematologic malignancies were previously thought to be primarily sporadic cancers without germline predispositions. However, over the last two decades, with the widespread use of next generation sequencing (NGS), there have been several genes have been identified that carry a risk of inheriting hematologic malignancies. Identification of individuals with hereditary hematologic malignancies (HHM) involves a high index of suspicion and careful attention to family history, clinical features, and variant allele frequency on somatic NGS pan els.Recent FindingsOver the last several years, many genetic ...
Source: Current Hematologic Malignancy Reports - October 24, 2022 Category: Hematology Source Type: research
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions
AbstractPurpose of ReviewThe clinical scenario for chronic myeloid leukemia patients rapidly changed after the introduction of tyrosine kinase inhibitors (TKIs). Second-generation TKIs as frontline treatment increased the rate of deep molecular responses without increasing the rate of overall survival. About 20% of patients experience resistance to these agents, needing alternative treatments. Here, we reviewed the possible mechanisms of resistance, available treatment, and new drugs developed to counteract and overcome resistance.Recent FindingsResults of novel TKIs have been recently reported, especially for the setting ...
Source: Current Hematologic Malignancy Reports - October 20, 2022 Category: Hematology Source Type: research
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies
AbstractPurpose of ReviewDespite the adoption of tyrosine kinases inhibitors (TKIs) as molecular targeted therapy in chronic myeloid leukemia, some patients do not respond to treatment and even experience disease progression. This review aims to give a broad summary of advances in understanding of the mechanisms of therapy resistance, as well as management strat egies that may overcome or prevent the emergence of drug resistance. Ultimately, the goal of therapy is the cure of CML, which will also require an increased understanding of the leukemia stem cell (LSC).Recent FindingsResistance to tyrosine kinase inhibitors ste...
Source: Current Hematologic Malignancy Reports - October 19, 2022 Category: Hematology Source Type: research
Circulating Tumor DNA in Lymphoma
This article discusses these various methods of ctDNA detection and the clinical context in which they have been applied to for a variety of lymphoma subtypes.Recent FindingsctDNA has been applied to a variety of subtypes of lymphoma and has been used in the context of genotyping somatic mutations and classification of disease, monitoring of response during treatment, detecting minimal residual disease even with radiographic remission, and predicting relapse and long-term survival outcomes. There are a variety of techniques used to measure ctDNA including digital polymerase chain reaction and next-generation sequencing tec...
Source: Current Hematologic Malignancy Reports - October 10, 2022 Category: Hematology Source Type: research
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation
AbstractPurpose of ReviewEmployment is an important indicator of health and functional recovery for hematopoietic cell transplantation (HCT) survivors and has significant social and economic impacts. Cancer survivors treated with conventional non-HCT therapy are known to be at a higher risk of unemployment or not returning to work after completion of therapy compared with the control population. However, the literature on return-to-work challenges among HCT survivors remains limited.Recent FindingsHere we summarize the evidence on prevalence and determinants of return-to-work challenges among HCT survivors using previously...
Source: Current Hematologic Malignancy Reports - October 4, 2022 Category: Hematology Source Type: research
